1 / 18

GROUP CASE PRESENTATION

GROUP CASE PRESENTATION. SATELLITE PHARMACY CLERKSHIP 2010/2011 GROUP B CASE: UROSEPSI S. PATIENT’ S CMR. PATIENT PARTICULARS. NAME: MISS ABC BED/WARD: C1/17 AGE: 70 DIAGNOSIS : UROSEPSIS DATE OF ADMISSION: 12/7/2010 DATE OF DISCHARGE : 8/8/2010. Brief overview : UROSEPSIS.

reece
Download Presentation

GROUP CASE PRESENTATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GROUP CASE PRESENTATION SATELLITE PHARMACY CLERKSHIP 2010/2011 GROUP B CASE: UROSEPSIS

  2. PATIENT’ S CMR

  3. PATIENT PARTICULARS • NAME: MISS ABC • BED/WARD: C1/17 • AGE: 70 • DIAGNOSIS : UROSEPSIS • DATE OF ADMISSION: 12/7/2010 • DATE OF DISCHARGE : 8/8/2010

  4. Brief overview : UROSEPSIS • Definition:sepsis (septicaemia syndrome) caused by urinary tract infection • Urosepsis in adults comprises approximately 25% of all sepsis cases and in most cases is due to complicated urinary tract infections (UTIs) • Classic presentation: fever, chills, hypotension in some patient • Patients who are more likely to develop urosepsis include: infant,elderlypatients, diabetics, immunosuppressed patients (such as transplant recipients), patients receiving cancer chemotherapy or corticosteroids and patients with acquired immunodeficiency syndrome(HIV)

  5. Clinical diagnostic criteria of sepsis • Associated with Systemic Inflammatory Response Syndrome(SIRS): i) Temperature > 38 C or < 36 C ii) Heart rate > 90 beats per minute iii)Respiratory rate > 20 breaths or PaC02 < 32 mmHg iv) White blood cells > 12 x 10^9/L

  6. For therapeutic purposes, the diagnostic criteria of sepsis should identify patients at an early stage of the syndrome, prompting urologists and intensive care specialists to search for and treat infection, initiate appropriate therapy, and monitor for organ failure and other complications • In the case of urosepsis the clinical evidence of UTI is based on symptoms, physical examination, sonographic and radiological features, and laboratory data, such as bacteriuria and leucocyturia.

  7. Pathophysiology of urosepsis • Micro-organisms reach the urinary tract by way of the ascending, haematogenous or lymphatic routes. For urosepsisto be established, from the urinary tract the pathogens have to reach the bloodstream. The risk of bacteraemia is increased in severe urogenital infections such as pyelonephritis and acute bacterial prostatitis, and is facilitated by obstruction.systemic inflammatory response syndrome (SIRS) is then triggered

  8. General Management of Urosepsis • Effective treatment eliminates the infectious sources, and improves organ perfusion. Treatment of urosepsiscomprises four basic strategies: i) supportive therapy (fluid replacement therapy for stabilisationand maintaining blood pressure, manage fluid and electrolyte balance) ii) antimicrobial therapy (initiate with broad spectrum antibiotic within in the first hour) iii) control or manageof the complicating factor, & iv) specific sepsis therapy(eg.corticosteroid, insulin, etc) All four strategies need to be started as early as possible.

  9. Appropriate and early diagnosis of sepsis is important to enable commencement of treatment without delay-if left untreated it can cause severe sepsis & septic shock • According to Kumar et al.’s data [7],we have 1 h to administer broad-spectrum antibiotics. We have 6 h to stabilisehaemodynamics according to early goal-directed therapy. We have 24 h to apply adjunctive therapy

  10. Severe Sepsis association with organ dysfunction, hypoperfusion or hypotension- may include but are not limited to lactic acidosis, oliguria or an acute alteration of mental status • Septicshock- Sepsis with hypotension despite adequate fluid resuscitation

  11. DRUG THERAPY GIVEN(based on CMR) • HYDROCHLOROTHIAZIDE • NIFEDIPINE • AMLODIPINE • PCM • LOVASTATION • TAZOCIN • OMEPRAZOLE • UNASYN • RANITIDINE • MAXOLON( • COLCHICINE • TICLIDOPINE • PREDNISOLONE • METOPROLOL • MIST KCL • NEUPOGEN • ALBUMIN • SYPLACTULOSE

  12. Hydrochlorothiazide( HCTZ) • INDICATION: Management of mild to moderate hypertension, treatment of edema in congestive heart failure, corticosteroid therapy and nephrotic syndrome • ACTION: Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium(&chloride) and water • Half life: 5.6-14.8 hour • Onset of action ~ 2hours (duration 6-12hours)

  13. DOSAGE IN ADULT • EDEMA(25-100mg/day , max 200mg/day) • HTN(12.5-50mg/day) In elderly patient : 12.5-25 mg once daily (from the prescription dose given is 25mg pood)

  14. Warning /Precaution • Should avoid in renal disease(ineffective) • Electrolyte disturbance(hypokalemia, hyponatremiaetc) can occur • May precipitate gout(cause hyperuricemia) • Use in caution with diabetes patient(may alter glucose control) • Use in caution in patient with high cholesterol • ADR: 1-10% :orthostatic hypotension, photosensitivity, hypokalemia, hyponatremia, anorexia, epigastric distress • Contraindications Hypersensitivity to thiazides, related diuretics, or sulfonamide-derived drugs; anuria; renal decompensation • Hepatic impairment: Minor alterations of fluid and electrolyte balance may precipitate hepatic coma; use drug with caution

  15. DRP detected: Drug-drug interactions 1) Hydrochlorothiazide + prednisolone Levels/effect of hydrochlorothiazide may be increased by corticosteroid (prednisolone) still can be used together 2) Hydrochlorothiazide + amlodipine The antihypertensive effect of amlodipine and thiazide diuretics may be additive. Management consists of monitoring blood pressure during coadministration, especially during the first 1 to 3 weeks of therapy.

  16. PATIENT CARE CONSIDERATIONS Administration/Storage • If drug is administered as single dose, give in morning. • Administer drug with food or milk to minimize GI irritation. • Store tablets in tightly closed container at room temperature

  17. Assessment/Interventions • Monitor patient's BP with patient lying down and standing. • Monitor serum potassium, calcium, magnesium, sodium, ABGs, uric acid. • Monitor renal (BUN, creatinine) and liver (ALT, AST) function tests. • Monitor blood glucose levels in diabetic patients. • Observe closely for anaphylaxis (shortness of breath, rash, edema) after first dose. • Report muscle weakness, cramps, nausea, blurred vision, or dizziness to health care provider • Advise patient to limit sodium intake for optimal drug effect • Caution patient to avoid sudden position changes to prevent orthostatic hypotension • Advise patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness

More Related